Skip to main content
Karlien Van Wesemael on Muck Rack

Karlien Van Wesemael

As seen in: PLOS ONE
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Karlien

Contact Karlien, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correction: β-Agonists Selectively Modulate Proinflammatory Gene Expression in Skeletal Muscle Cells via Non-Canonical Nuclear Crosstalk Mechanisms

|
By Krzysztof Kolmus, Marleen Van Troys, Karlien Van Wesemael, Christophe Ampe
| PLOS ONE
Loading metrics The start phase iso panel in Fig 6A is incorrect as it is an inadvertent duplication of the start phase veh panel. The updated Fig 6 is provided here in which the start phase iso panel is corrected. Fig 6. C2C12 myotubes secrete factors that promote the migration of C2C12 myoblasts. C2C12 myotubes were treated for 24 hrs with veh, iso, TNF and iso+TNF. Conditioned medium was prepared as described in Materials and Methods and applied to C2C12 myoblasts.
Open in Who Shared Issue with article?

β-agonists selectively modulate proinflammatory gene expression in skeletal muscle cells via non-canonical nuclear crosstalk mechanisms

|
By Karlien Van Wesemael, Krzysztof Kolmus, Marleen Van Troys, Christophe Ampe
| pubpeer.com
Comments PLoS ONE (2014) - pubmed: 24603712 doi: 10.1371/journal.pone.0090649 issn: 1932-6203 Krzysztof Kolmus, Marleen Van Troys, Karlien Van Wesemael, Christophe Ampe, Guy Haegeman, Jan Tavernier, Sarah Gerlo
Open in Who Shared Issue with article?

Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies

|
By Fritz Offner, Dorien Clarisse, Karlien Van Wesemael, Jan Tavernier
| PLOS
Glucocorticoids (GCs) are a cornerstone in the treatment of lymphoid malignancies such as multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Yet, prolonged GC use is hampered by deleterious GC-related side effects and the emergence of GC resistance.
Open in Who Shared Issue with article?
See all 3 articles